Sprint Bioscience

Tune in to hear Sprint Bioscience featured on the Market Makers podcast🎙️CEO Johan Emilsson joins for an interview.

Market Makers is one of Sweden’s largest finance podcasts, focusing on investments in growth and technology stocks. Since its launch in 2017, the podcast has accumulated over 4 million listens and built a loyal audience. New episodes are released every Thursday, featuring stock cases, market insights, and analysis across sectors.

In the latest episode, Johan talks about what we do at Sprint Bioscience and, most importantly, how we do it, while also answering questions about our business and strategy.

📻 Listen to the episode here (available in Swedish): https://shows.acast.com/marketmakers/episodes/434-kina-och-norgerisken

Today at AACR 2026 by American Association for Cancer Research (AACR) we are presenting data from our DCPS program, supporting DCPS inhibition as a promising therapeutic strategy for patients with acute myeloid leukemia (AML). The findings go beyond efficacy, providing deeper biological insight into DCPS and highlighting its potential role in improving patient stratification. Sprint Bioscience is represented by CSO Martin Andersson and Associate Principal Scientist Madhurendra Singh. Come by and discuss the data with us!
📍 Biomarkers Predictive of Therapeutic Benefit 6
🗓️ Wednesday, April 22 | Poster Section 41, Board 18

At a time when the global cancer burden continues to rise, scientific progress cannot afford silos, slowdowns, or hesitation. Breakthroughs happen when knowledge is shared, challenged, and accelerated. That is why Sprint Bioscience is proud to participate in the American Association for Cancer Research (AACR) Annual Meeting 2026, the world’s largest and most influential cancer research convening.

Ahead of the main meeting, our CSO and co‑founder Martin Andersson participated in the AACR Oncology Industry Partnering Event (April 16–17), engaging with leaders across biotech and pharma. These discussions are where science meets strategy and where discoveries begin their journey toward patients.

The Annual Meeting (April 17–22) is currently underway, where Madhurendra Singh will present new preclinical data from our DCPS program. The poster highlights findings supporting DCPS inhibition as a potential therapeutic strategy for patients with acute myeloid leukemia (AML). Beyond efficacy, the data deepens the biological understanding of DCPS and underscore its potential to improve patient stratification.
🔔Wednesday, April 22 Biomarkers Predictive of Therapeutic Benefit 6 📍Location: Poster Section 41 Poster Board Number: 18

Events like AACR matter because no single lab, company, or discipline can solve cancer alone. In times of scientific complexity, geopolitical uncertainty, and mounting healthcare pressure, platforms for exchange and collaboration are not optional, they are essential.
Cancer does not wait. Neither can drug discovery.